Tags

Type your tag names separated by a space and hit enter

Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration.
Biologics. 2020; 14:83-94.B

Abstract

Here we discuss antibody, cell and gene-based therapies that are currently available and under investigation for both wet and dry age-related macular degeneration (AMD). We initially discuss ocular anatomy, AMD modelling as well as the underlying pathophysiology of AMD. The antibody-based trials which have revolutionised the management of wet AMD are reviewed. The latest concepts in antibody therapy for wet AMD such as the port delivery systems, bispecific antibodies, designed ankyrin repeat protein (DARPINs) and brolucizumab are explored. Furthermore, the antibody-based trials targeting the complement pathway to reduce progression of geographic atrophy (GA) in dry AMD are discussed. Stem cell therapy and gene therapy are novel treatment modalities with no established clinical use in wet or dry AMD. Here, we discuss their efficacy so far in clinical trials. Their benefits and risk in the treatment of both wet and dry AMD are evaluated.

Authors+Show Affiliations

Clinical Neurosciences Research Group, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.Clinical Neurosciences Research Group, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32982165

Citation

Akyol, Engin, and Andrew Lotery. "Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration." Biologics : Targets & Therapy, vol. 14, 2020, pp. 83-94.
Akyol E, Lotery A. Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration. Biologics. 2020;14:83-94.
Akyol, E., & Lotery, A. (2020). Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration. Biologics : Targets & Therapy, 14, 83-94. https://doi.org/10.2147/BTT.S252581
Akyol E, Lotery A. Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration. Biologics. 2020;14:83-94. PubMed PMID: 32982165.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration. AU - Akyol,Engin, AU - Lotery,Andrew, Y1 - 2020/09/11/ PY - 2020/06/24/received PY - 2020/08/04/accepted PY - 2020/9/28/entrez PY - 2020/9/29/pubmed PY - 2020/9/29/medline KW - choroidal neovascularisation KW - gene therapy KW - geographic atrophy KW - macular degeneration KW - monoclonal antibodies KW - stem cell therapy SP - 83 EP - 94 JF - Biologics : targets & therapy JO - Biologics VL - 14 N2 - Here we discuss antibody, cell and gene-based therapies that are currently available and under investigation for both wet and dry age-related macular degeneration (AMD). We initially discuss ocular anatomy, AMD modelling as well as the underlying pathophysiology of AMD. The antibody-based trials which have revolutionised the management of wet AMD are reviewed. The latest concepts in antibody therapy for wet AMD such as the port delivery systems, bispecific antibodies, designed ankyrin repeat protein (DARPINs) and brolucizumab are explored. Furthermore, the antibody-based trials targeting the complement pathway to reduce progression of geographic atrophy (GA) in dry AMD are discussed. Stem cell therapy and gene therapy are novel treatment modalities with no established clinical use in wet or dry AMD. Here, we discuss their efficacy so far in clinical trials. Their benefits and risk in the treatment of both wet and dry AMD are evaluated. SN - 1177-5475 UR - https://www.unboundmedicine.com/medline/citation/32982165/Gene_Cell_and_Antibody_Based_Therapies_for_the_Treatment_of_Age_Related_Macular_Degeneration_ L2 - https://dx.doi.org/10.2147/BTT.S252581 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.